AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche (SIX: RO, ROG; OTCQX: RHHBY). The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.
